AMENDMENT NO. 1 TO LICENSE AGREEMENTGlobal Blood Therapeutics, Inc. • August 8th, 2022 • Pharmaceutical preparations
This Amendment No.1 (the “Amendment”) to the License Agreement effective as of March 12, 2021 (the “Agreement”) is made and entered into as of April 15th, 2022 (the “Amendment Effective Date”) by and between Sanofi, a French corporation located at 54, rue La Boétie, 75008 Paris, France (“Sanofi”) and Global Blood Therapeutics, Inc., a Delaware corporation located at 181 Oyster Point Boulevard, South San Francisco, CA, 94080 USA (“Licensee”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement.
